List view / Grid view
12 December 2009 | By
The promise of stem cell-based therapy is predicated on harnessing the plasticity of stem cell phenotypes to repair or replace damaged tissues. As technologies for detecting, isolating, modifying, and tracking stem cells improve, the very definition of what constitutes a stem cell is now an open question. Addressing this fundamental…
12 December 2009 | By
The 4th annual Stem Cells World Congress and exhibition will be held in South San Francisco, the Birthplace of Biotechnology. This year there are two parallel tracks focused specifically on...
29 May 2009 | By
Nearly fifty years ago, it was hypothesised that terminally differentiated cells such as fibroblasts could be forced to take on a pluripotent state, similar to the embryonic stem cells (ES cells). The basis of the concept is the observation that all cell types, with minor exceptions, have the same genetic…
Dr Paul Andrews (Senior Scientist, ITI Stem Cell Technology Programme, University of Dundee), Professor Peter Andrews (co-Director of the Centre for Stem Cell Biology, University of Sheffield), Fergus McKenzie PhD. (Programme Manager, ITI-Life Sciences), Dr Stephen Minger (Senior Lecturer in Stem Cell Biology, Kings College London) and Will Rust (Section…
10 January 2009 | By
When talking about stem cell research and its contribution to medical innovation, distinction should be made between embryonic stem cell research, believed to have almost infinite potential but with quite long-term perspectives, and adult stem cell research, which is already offering new therapeutic applications for otherwise incurable diseases. Today, adult…
3 December 2008 | By
The development of pharmaceuticals and screening the biological activity of test compounds is a multi-staged process spanning from small molecule design and synthesis, in vitro testing, and compound evaluation in vivo using animal and human trials. The expense of this process escalates as a compound advances further into the development…
3 December 2008 | By
This year’s congress will include the Keynote Speakers Bernard Siegal, Executive Director at the Genetics Policy Institute, Jan Nolta, Director at the Stem Cell Programme in the University of California and Carolyn Compton, Director at the Biorepositories and Biospecimen Research in the National Cancer Institute.
29 September 2008 | By
The pharmaceutical industry is at a crossroads: Research and Development costs continue to rise, whilst the pipeline of ‘blockbuster’ drugs is looking decidedly sparse for many of the major pharmaceutical companies. This state of affairs is compounded by the high attrition rates (>80%) of drug candidates, when they get to…
2 August 2008 | By
Stem cells have two important characteristics that distinguish them from other cells: the ability to self-renew through cell division for a prolonged period, and to differentiate into multiple cells with specialised functions. The power of stem cells for tissue development, regeneration and renewal has been well known to embryologists for…
